SET oncogene is upregulated in pediatric acute lymphoblastic leukemia

Tumori

Volumn 98, Issue 2, 2012, Pages 252-256

  Ekmekci, Sema Sirma ^a   Ekmekci, Cumhur G ^a   Kandilci, Ayten ^b   Gulec, Cagri ^c   Akbiyik, Meral ^c   Emrence, Zeliha ^a   Abaci, Neslihan ^a   Karakas, Zeynep ^c   Agaoglu, Leyla ^c   Unuvar, Aysegul ^c   Anak, Sema ^c   Devecioglu, Omer ^c   Ustek, Duran ^a   Grosveld, Gerard ^d   Ozbek, Ugur ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b GEBZE TECHNICAL UNIVERSITY   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Acute lymphoblastic leukemia; Pediatric ALL; SET; SET over expression

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER CLASSIFICATION; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; INFANT; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OVERALL SURVIVAL; PEDIATRICS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; CHILD; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; METABOLISM; PRESCHOOL CHILD;

CHAPERONE; SET PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER; TUMOR PROTEIN;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE CHAPERONES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM PROTEINS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84864873918     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/1088.11938     Document Type: Article

References (24)

1. Harrison CJ, Foroni L: Cytogenetics and molecular genetics of acute lymphoblastic leukemia. Rev Clin Exp Hematol, 6: 91-113, 2002.
2. Pui CH, Relling MV, Downing JR: Acute lymphoblastic leukemia. N Engl J Med, 350: 1535-1548, 2004.
3. Raimondi SC: Cytogenetics of acute leukemias. In: Childhood Leukemias, CH Pui, Ed, pp 235-271, Cambridge University Press, Cambridge, 2006.
4. Mulligan CG: Genomic analysis of acute leukemia. Int J Lab Hematol, 4: 384-397, 2009.
5. Collins-Underwood JR, Mulligan CG: Genomic profiling of high risk acute lymphoblastic leukemia. Leukemia, 24: 1676-1685, 2010.
6. Nagata K, Kawase H, Handa H, Yano K, Yamasaki M, Ishimi Y, Okuda A, Kikuchi A, Matsumoto K: Replication factor encoded by a putative oncogene, set, associated with myeloid leukemogenesis. Proc Natl Acad Sci USA, 92: 4279-4283, 1995.
7. Miyaji-Yamaguchi M, Okuwaki M, Nagata K: Coiled-coil structure-mediated dimerization of template activating factor-I is critical for its chromatin remodeling activity. J Mol Biol, 290: 547-557, 1999. (Pubitemid 29324838)
8. Seo SB, MacNamara P, Heo S, Turner A, Lane WS, Chakravarti D: Regulation of histon acetylation and transcription by INHAT, a human cellular compex containing the SET oncoprotein. Cell, 104: 119-130, 2001. (Pubitemid 32144977)
9. Morita A, Suziki N, Matsumato Y, Hirano K, Enomoto A, Zhu J, Sakai K: P41 as a possible marker for cell death is generated by caspase cleavage of p42 SET beta in irradiated MOLT-4 cells. Biochem Biophys Res Commun, 278: 627-632, 2000.
10. Fan Z, Baresford PJ, Oh DY, Zhang D, and Lieberman J: Tumor suppressor NM23-H1 is a granzyme-A activated DNase during CTL mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell, 112: 659-672, 2003. (Pubitemid 36331778)
11. Li M, Makkinje A, Damuni Z: The myeloid leukemia associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem, 271: 11059-11062, 1996. (Pubitemid 26155931)
12. Canela N, Rodrigez-Vilarrupla A, Estanyol JM, Diaz C, Pujol MJ, Angell N, Bachs O: The SET protein regulates G2/M transition by modulating cyclin B-cyclin-dependent kinase B activity. J Biol Chem, 278: 1158-1164, 2003. (Pubitemid 36790797)
13. Klooster JP, Leeuven I, Scheres N, Anthony EC, Hordijk PL: Rac1 induces cell migration requires membrane recruitment of the nuclear oncogene SET. EMBO J, 26: 336-345, 2007. (Pubitemid 46160935)
14. Compagnone NA. Zhang P, Vigne JL, Mellon SH: Novel role for nuclear phosphoprotein SET in transcriptional activation of p450c17 and initiation of neurosteroidogenesis. Mol Endocrinol, 14: 875-888, 2000. (Pubitemid 32260500)
15. Brennan CM, Gallouzi IE, Steitz JA: Protein ligands to HuR modulate its interaction with target mRNAs in vivo. J Cell Biol, 151: 1-14, 2000.
16. Adachi Y, Pavlakis GN, Copeland TD: Identification of in vivo phosphorylation sites of SET, a nuclear phosphoprotein encoded by the translocation breakpoint in acute undifferentiated leukemia. FEBS Lett, 340: 231-235, 1994. (Pubitemid 24080956)
17. von Lindern M, Breems D, van Baal S, Adriaansen H, Grosveld G: Characterization of the translocation breakpoint sequences of two DEK-CAN fusion genes present in t(6;9) acute myeloid leukemia and a SET-CAN fusion gene found in a case of acute undifferentiated leukemia. Genes Chromosomes Cancer, 5: 227-234, 1992.
18. Quentmeier H, Björn S, Röhrs S, Romani S, Zaborski M, McLeod RAF, Drexler HG: SET-NUP214 fusion in acute myeloid leukemia- and T-cell acute lymphoblastic leukemia-derived cell lines. J Hematol Oncol, 2: 3, 2009.
19. Kim J, Lee SG, Song J, Kim SJ, Rha SY, Lee KA, Park TS, Choi JR: Molecular characterization of alternative SET-NUP214 fusion transcripts in a case of acute undifferentiated leukemia. Cancer Genet Cytogenet, 201: 73-80, 2010.
20. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW: The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell, 8: 355-368, 2005. (Pubitemid 41579831)
21. Carlson SG, Eng E, Kim EG, Perlman EJ, Kopeland TD, Ballermann BJ: Expression of SET an inhibitor of protein phosphatase 2A in renal development and Wilms' tumor. J Am Soc Nephrol, 9: 1873-1880, 1998. (Pubitemid 28443484)
22. Fukukawa C, Shima H, Tanuma R, Ogawa K, Kikuchi K: Upregulation of I2PP2A/SET gene expression in rat primary hepatomas and regenerating livers. Cancer Lett, 161: 89-95, 2000.
23. Christensen DJ, Bond KM, Volkheimer AD, Oddo J, Chen Y, Gockerman JP, Moore JO, Dieh LF, de Castro CM, Vitek MP, Weinberg JB: The SET oncogene, a potent PP2A inhibitor, is elevated in CLL and antagonism of SET induces apoptosis. 51th ASH Annual Meeting and Exposition. Blood, 104: 802, 2009 (abstract).
24. Switzer CH, Cheng RY, Vitek TM, Christensen DJ, Wink DA, Vitek MP: Targeting SET/I(2)PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene 30(22): 2504-2513, 2011. Epub 2011 Feb 7.